TEAD2 and cancer: Within BrCa, pathways ETF and E2F were significantly enriched (P = 6.75 × 10−10, P = 2.8 × 10−6) in ER+ BrCa and “Proteoglycans in cancer” in ER− BrCa (P = 1.4 × 10−5).